Angiogenesis in endocrine tumors

被引:254
作者
Turner, HE
Harris, AL
Melmed, S
Wass, JAH
机构
[1] Churchill Hosp, Dept Endocrinol, Oxford OX3 7LJ, England
[2] John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund, Mol Angiogenesis Grp, Oxford OX3 9DU, England
[3] Cedars Sinai Med Ctr, Davis Res Inst, Los Angeles, CA 90048 USA
关键词
D O I
10.1210/er.2002-0008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Angiogenesis is the process of new blood vessel development from preexisting vasculature. Although vascular endothelium is usually quiescent in the adult, active angiogenesis has been shown to be an important process for new vessel formation, tumor growth, progression, and spread. The angiogenic phenotype depends on the balance of proangiogenic growth factors such as vascular endothelial growth factor (VEGF) and inhibitors, as well as interactions with the extracellular matrix, allowing for endothelial migration. Endocrine glands are typically vascular organs, and their blood supply is essential for normal function and tight control of hormone feedback loops. In addition to metabolic factors such as hypoxia, the process of angiogenesis is also regulated by hormonal changes such as increased estrogen, IGF-I, and TSH levels. By measuring microvascular density, differences in angiogenesis have been related to differences in tumor behavior, and similar techniques have been applied to both benign and malignant endocrine tumors with the aim of identification of tumors that subsequently behave in an aggressive fashion. In contrast to other tumor types, pituitary tumors are less vascular than normal pituitary tissue, although the mechanism for this observation is not known. A relationship between angiogenesis and tumor size, tumor invasiveness, and aggressiveness has been shown in some pituitary tumor types, but not in others. There are few reports on the role of microvascular density or angiogenic factors in adrenal tumors. The mechanism of the vascular tumors, which include adrenomedullary tumors, found in patients with Von Hippel Lindau disease has been well characterized, and clinical trials of antiangiogenic therapy are currently being performed in patients with Von Hippel Lindau disease. Thyroid tumors are more vascular than normal thyroid tissue, and there is a clear correlation between increased VEGF expression and more aggressive thyroid tumor behavior and metastasis. Although parathyroid tissue induces angiogenesis when autotransplanted and PTH regulates both VEGF and MMP expression, there are few studies of angiogenesis and angiogenic factors in parathyroid tumors. An understanding of the balance of angiogenesis in these vascular tumors and mechanisms of vascular control may assist in therapeutic decisions and allow appropriately targeted treatment.
引用
收藏
页码:600 / 632
页数:33
相关论文
共 415 条
[1]   Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4) [J].
Achen, MG ;
Jeltsch, M ;
Kukk, E ;
Mäkinen, T ;
Vitali, A ;
Wilks, AF ;
Alitalo, K ;
Stacker, SA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (02) :548-553
[2]   Serum vascular endothelial growth factor concentrations in postmenopausal women: the effect of hormone replacement therapy [J].
Agrawal, R ;
Prelevic, G ;
Conway, GS ;
Payne, NN ;
Ginsburg, J ;
Jacobs, HS .
FERTILITY AND STERILITY, 2000, 73 (01) :56-60
[3]   SUPPRESSION OF RETINAL NEOVASCULARIZATION IN-VIVO BY INHIBITION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR (VEGF) USING SOLUBLE VEGF-RECEPTOR CHIMERIC PROTEINS [J].
AIELLO, LP ;
PIERCE, EA ;
FOLEY, ED ;
TAKAGI, H ;
CHEN, H ;
RIDDLE, L ;
FERRARA, N ;
KING, GL ;
SMITH, LEH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (23) :10457-10461
[4]  
Akagi Y, 1998, CANCER RES, V58, P4008
[5]   Parathyroid hormone-related peptide is a potent tumor angiogenic factor [J].
Akino, K ;
Ohtsuru, A ;
Kanda, K ;
Yasuda, A ;
Yamamoto, T ;
Akino, Y ;
Naito, S ;
Kurokawa, M ;
Iwahori, N ;
Yamashita, S .
ENDOCRINOLOGY, 2000, 141 (11) :4313-4316
[6]   HUMAN AND MURINE PITUITARY EXPRESSION OF LEUKEMIA INHIBITORY FACTOR - NOVEL INTRAPITUITARY REGULATION OF ADRENOCORTICOTROPIN HORMONE SYNTHESIS AND SECRETION [J].
AKITA, S ;
WEBSTER, J ;
REN, SG ;
TAKINO, H ;
SAID, J ;
ZAND, O ;
MELMED, S .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (03) :1288-1298
[7]   Pituitary-directed leukemia inhibitory factor transgene forms Rathke's cleft cysts and impairs adult pituitary function - A model for human pituitary Rathke's cysts [J].
Akita, S ;
Readhead, C ;
Stefaneanu, L ;
Fine, J ;
TampanaruSarmesiu, A ;
Kovacs, K ;
Melmed, S .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (10) :2462-2469
[8]   Increased angiogenesis in papillary thyroid carcinoma but lack of prognostic importance [J].
Akslen, LA ;
LiVolsi, VA .
HUMAN PATHOLOGY, 2000, 31 (04) :439-442
[9]  
Ali SH, 1999, MOL CELL ENDOCRINOL, V152, P1
[10]   NEW PERSPECTIVES IN THE FUNCTION OF PITUITARY FOLLICULO-STELLATE CELLS [J].
ALLAERTS, W ;
CARMELIET, P ;
DENEF, C .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1990, 71 (02) :73-81